

**DONAL MCGOEY PHARMACY LIMITED
ACCOUNTS 2025**

**DONAL MCGOEY PHARMACY LIMITED
REPORTS AND
FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2025**

DONAL MCGOEY PHARMACY LIMITED

COMPANY INFORMATION

DIRECTORS Jonathan McGoey
Georgina McGoey

COMPANY SECRETARY Jonathan McGoey

REGISTERED NUMBER 371564

REGISTERED OFFICE 66 Market Street
Ardee
Co. Louth
A92K443

INDEPENDENT AUDITOR OSK Audit Limited
East Point Plaza
East Point
Dublin 3

BANKERS Bank of Ireland
Ardee
Co. Louth

DONAL MCGOEY PHARMACY LIMITED

CONTENTS

	Page
Special auditor's report	1 - 4
Abridged statement of financial position	5
Notes to the abridged financial statements	6 - 14

DONAL MCGOEY PHARMACY LIMITED

INDEPENDENT AUDITOR'S SPECIAL REPORT TO THE MEMBERS OF DONAL MCGOEY PHARMACY LIMITED **PURSUANT TO SECTION 356 OF THE COMPANIES ACT 2014**

-

On 8 December 2025 we reported as auditor of Donal McGoey Pharmacy Limited to the directors of the company on the abridged financial statements for the year ended 31 October 2025 on pages 5 to 14 and our report was as follows:

We have examined:

- (i) the abridged financial statements for the year ended 31 October 2025 on pages 5 to 14 which the directors of Donal McGoey Pharmacy Limited propose to annex to the Annual Return of the company; and
- (ii) the financial statements to be laid before the Annual General Meeting which form the basis for those abridged financial statements.

RESPECTIVE RESPONSIBILITIES OF DIRECTORS AND AUDITOR

It is your responsibility to prepare the abridged financial statements which comply with the Companies Act 2014. It is our responsibility to form an independent opinion that the directors are entitled under Section 352 of the Companies Act 2014 to annex abridged financial statements to the annual return of the company and that those abridged financial statements have been properly prepared pursuant to Section 353 of that Act (exemptions available for small companies) and to report our opinion to you.

This report is made solely to the directors in accordance with Section 356 of the Companies Act 2014. Our work was undertaken so that we might state to the directors those matters we are required to state to them in our report under Section 356 of the Companies Act 2014 and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the directors for our work, for this report, or for the opinions we have formed.

BASIS OF OPINION

We have carried out the procedures we consider necessary to confirm, by reference to the financial statements, that the company is entitled to annex abridged financial statements to the Annual Return of the company and that the abridged financial statements are properly prepared. The scope of our work for the purpose of this report did not include examining or dealing with events after the date of our report on the full financial statements.

OPINION ON FINANCIAL STATEMENTS

In our opinion the directors are entitled under Section 352 of the Companies Act 2014 to annex to the Annual Return of the company the abridged financial statements and those abridged financial statements have been properly prepared pursuant to the provisions of Section 353 of that Act (exemptions available for small sized companies).

OTHER INFORMATION

On 8 December 2025 we reported as auditor of Donal McGoey Pharmacy Limited to the members on the company's financial statements for the year ended 31 October 2025 to be laid before its Annual General Meeting and our report was as follows:

"We have audited the financial statements of Donal McGoey Pharmacy Limited (the 'company') for the year ended 31 October 2025, which comprise the Statement of Financial Position and the notes to the financial statements, including a summary of significant accounting policies set out in note 2. The financial reporting framework that has been applied in their preparation is Irish law and Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' issued in the United Kingdom by the Financial Reporting Council.

DONAL MCGOEY PHARMACY LIMITED

INDEPENDENT AUDITOR'S SPECIAL REPORT TO THE MEMBERS OF DONAL MCGOEY PHARMACY LIMITED (CONTINUED) **PURSUANT TO SECTION 356 OF THE COMPANIES ACT 2014**

In our opinion, the financial statements:

- give a true and fair view of the assets, liabilities and financial position of the company as at 31 October 2025 and of its loss for the year then ended;
- have been properly prepared in accordance with Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'; and
- have been properly prepared in accordance with the requirements of the Companies Act 2014.

BASIS FOR OPINION

We conducted our audit in accordance with International Standards on Auditing (Ireland) (ISAs (Ireland)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of financial statements in Ireland, including the Ethical Standard for Auditors (Ireland) issued by the Irish Auditing and Accounting Supervisory Authority (IAASA), and the provisions available for small entities, in the circumstances set out in note 13 to the financial statements, and we have fulfilled our other ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

CONCLUSIONS RELATING TO GOING CONCERN

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from the date when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

DONAL MCGOEY PHARMACY LIMITED

INDEPENDENT AUDITOR'S SPECIAL REPORT TO THE MEMBERS OF DONAL MCGOEY PHARMACY LIMITED (CONTINUED) **PURSUANT TO SECTION 356 OF THE COMPANIES ACT 2014**

OTHER INFORMATION

The directors are responsible for the other information. The other information comprises the information included in the Annual report, other than the financial statements and our Auditor's report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

OPINION ON THE OTHER MATTERS PRESCRIBED BY THE COMPANIES ACT 2014

In our opinion, based on the work undertaken in the course of the audit, we report that:

- the information given in the Directors' Report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Directors' Report has been prepared in accordance with applicable legal requirements.

We have obtained all the information and explanations which, to the best of our knowledge and belief, are necessary for the purposes of our audit.

In our opinion the accounting records of the company were sufficient to permit the financial statements to be readily and properly audited, and the financial statements are in agreement with the accounting records.

MATTERS ON WHICH I AM REQUIRED TO REPORT BY EXCEPTION

Based on the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified any material misstatements in the Directors' Report.

The Companies Act 2014 requires us to report to you if, in our opinion, the requirements of any of sections 305 to 312 of the Act, which relate to disclosures of directors' remuneration and transactions are not complied with by the company. We have nothing to report in this regard.

RESPECTIVE RESPONSIBILITIES AND RESTRICTIONS ON USE

RESPONSIBILITIES OF DIRECTORS

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the management either intends to liquidate the company or to cease operations, or has no realistic alternative but to do so.

DONAL MCGOEY PHARMACY LIMITED

INDEPENDENT AUDITOR'S SPECIAL REPORT TO THE MEMBERS OF DONAL MCGOEY PHARMACY LIMITED (CONTINUED)
PURSUANT TO SECTION 356 OF THE COMPANIES ACT 2014

AUDITORS' RESPONSIBILITIES FOR THE AUDIT OF THE FINANCIAL STATEMENTS

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditor's Report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (Ireland) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is located on the IAASA's website at: <http://www.iaasa.ie>. This description forms part of our Auditor's Report."

THE PURPOSE OF OUR AUDIT WORK AND TO WHOM WE OWE OUR RESPONSIBILITIES

This report is made solely to the company's members, as a body, in accordance with Section 391 of the Companies Act 2014. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an Auditor's Report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members, as a body, for our audit work, for this report, or for the opinions we have formed.

Dylan Byrne
for and on behalf of
OSK Audit Limited
Statutory Audit Firm
East Point Plaza
East Point
Dublin 3

8 December 2025

DONAL MCGOEY PHARMACY LIMITED

-

ABRIDGED STATEMENT OF FINANCIAL POSITION
AS AT 31 OCTOBER 2025

	Note	2025 €	2024 €
<u>Fixed assets</u>			
Tangible assets	6	169,495	217,365
		<u>169,495</u>	<u>217,365</u>
<u>Current assets</u>			
Stocks	7	685,841	693,346
Debtors: amounts falling due within one year	8	4,685,556	4,662,516
Cash at bank and in hand		629,985	642,508
		<u>6,001,382</u>	<u>5,998,370</u>
Creditors: amounts falling due within one year	9	(804,733)	(821,296)
		<u>5,196,649</u>	<u>5,177,074</u>
<u>Net current assets</u>		<u>5,196,649</u>	<u>5,177,074</u>
<u>Total assets less current liabilities</u>		<u>5,366,144</u>	<u>5,394,439</u>
<u>Provisions for liabilities</u>			
Deferred tax	10	-	(697)
		<u>-</u>	<u>(697)</u>
<u>Net assets</u>		<u>5,366,144</u>	<u>5,393,742</u>
<u>Capital and reserves</u>			
Called up share capital presented as equity		200	200
Profit and loss account		5,365,944	5,393,542
<u>Shareholders' funds</u>		<u>5,366,144</u>	<u>5,393,742</u>

These financial statements have been prepared in accordance with the small companies regime.

We, as directors of Donal McGoey Pharmacy Limited, state that:

The company has relied on the specific exemptions contained in section 352 of the Companies Act 2014; the company has done so on the grounds that it is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 of the Companies Act 2014.

The financial statements were approved and authorised for issue by the board:

Jonathan McGoey
Director

Georgina McGoey
Director

Date: 8 December 2025

The notes on pages 6 to 14 form part of these financial statements.

DONAL MCGOEY PHARMACY LIMITED

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 OCTOBER 2025

1. GENERAL INFORMATION

These financial statements comprising the Statement of income and retained earnings, the Statement of financial position and the related notes constitute the individual financial statements of Donal McGoey Pharmacy Limited for the financial year ended 31 October 2025.

Donal McGoey Pharmacy Limited is a private company limited by shares, incorporated in the Republic of Ireland. The Registered Office is at 66 Market Street, Ardee, Co. Louth. The principal place of business is the same as above. The nature of the company's operations and its principal activities are set out in the Directors Report.

Currency

The financial statements have been presented in Euro (€) which is also the functional currency of the company.

2. ACCOUNTING POLICIES

2.1 BASIS OF PREPARATION OF FINANCIAL STATEMENTS

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention modified to include certain items at fair value. The financial reporting framework that has been applied is the Companies Act 2014 and FRS 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland.

The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise judgement in applying the Company's accounting policies.

The following principal accounting policies have been applied:

2.2 VALUATION OF INVESTMENTS

Investments in unlisted company shares, whose market value can be reliably determined, are remeasured to market value at each reporting date. Gains and losses on remeasurement are recognised in the Statement of Income and Retained Earnings for the period. Where market value cannot be reliably determined, such investments are stated at historic cost less impairment.

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2025

2. ACCOUNTING POLICIES (CONTINUED)

2.3 REVENUE

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Sale of goods

Revenue from the sale of goods is recognised when all of the following conditions are satisfied:

- the company has transferred the significant risks and rewards of ownership to the buyer;
- the company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;
- the amount of revenue can be measured reliably;
- it is probable that the company will receive the consideration due under the transaction; and
- the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Rendering of services

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:

- the amount of revenue can be measured reliably;
- it is probable that the company will receive the consideration due under the contract;
- the stage of completion of the contract at the end of the reporting period can be measured reliably; and
- the costs incurred and the costs to complete the contract can be measured reliably.

2.4 INTANGIBLE ASSETS

Intangible assets are initially recognised at cost. After recognition, under the cost model, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

At each reporting date the company assesses whether there is any indication of impairment. If such indication exists, the recoverable amount of the asset is determined which is the higher of its fair value less costs to sell and its value in use. An impairment loss is recognised where the carrying amount exceeds the recoverable amount.

All intangible assets are considered to have a finite useful life. If a reliable estimate of the useful life cannot be made, the useful life shall not exceed ten years.

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2025

2. ACCOUNTING POLICIES (CONTINUED)

2.5 TANGIBLE FIXED ASSETS

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

At each reporting date the company assesses whether there is any indication of impairment. If such indication exists, the recoverable amount of the asset is determined which is the higher of its fair value less costs to sell and its value in use. An impairment loss is recognised where the carrying amount exceeds the recoverable amount.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Motor vehicles	-	20.0%
Fixtures & fittings & equipment	-	12.5%

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

2.6 STOCKS

Stocks are stated at the lower of cost and net realisable value, being the estimated selling price less costs to complete and sell. Cost is based on the cost of purchase on a first in, first out basis. Work in progress and finished goods include labour and attributable overheads.

At each reporting date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in profit or loss.

2.7 DEBTORS

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

2.8 CASH AND CASH EQUIVALENTS

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

2.9 CREDITORS

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2025

2. ACCOUNTING POLICIES (CONTINUED)

2.10 GOVERNMENT GRANTS

Grants are accounted under the accruals model as permitted by FRS 102. Grants relating to expenditure on tangible fixed assets are credited to profit or loss at the same rate as the depreciation on the assets to which the grant relates. The deferred element of grants is included in creditors as deferred income.

Grants of a revenue nature are recognised in the Statement of Income and Retained Earnings in the same period as the related expenditure.

2.11 LEASED ASSETS: THE COMPANY AS LESSEE

Assets obtained under hire purchase contracts and finance leases are capitalised as tangible fixed assets. Assets acquired by finance lease are depreciated over the shorter of the lease term and their useful lives. Assets acquired by hire purchase are depreciated over their useful lives. Finance leases are those where substantially all of the benefits and risks of ownership are assumed by the company. Obligations under such agreements are included in creditors net of the finance charge allocated to future periods. The finance element of the rental payment is charged to profit or loss so as to produce a constant periodic rate of charge on the net obligation outstanding in each period.

2.12 PENSIONS

Defined contribution pension plan

The company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the company pays fixed contributions into a separate entity. Once the contributions have been paid the company has no further payment obligations.

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Statement of Financial Position. The assets of the plan are held separately from the company in independently administered funds.

DONAL MCGOEY PHARMACY LIMITED

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 OCTOBER 2025

2. ACCOUNTING POLICIES (CONTINUED)

2.13 CURRENT AND DEFERRED TAXATION

The tax expense for the year comprises current and deferred tax. Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the reporting date, except that:

- The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
- Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date.

3. EMPLOYEES

The average monthly number of employees, including the directors, during the year was as follows:

	2025 No.	2024 No.
Directors	2	2
Sales	40	40
	<u>42</u>	<u>42</u>

4. DIRECTORS' REMUNERATION

	2025 €	2024 €
Directors' emoluments	379,033	359,270
Company contributions to defined contribution pension schemes	67,200	71,070
	<u>446,233</u>	<u>430,340</u>

DONAL MCGOEY PHARMACY LIMITED

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2025

5. INTANGIBLE ASSETS

	Goodwill €
Cost	
At 1 November 2024	1,250,000
At 31 October 2025	1,250,000
Amortisation	
At 1 November 2024	1,250,000
At 31 October 2025	1,250,000
Net book value	
At 31 October 2025	-
<i>At 31 October 2024</i>	-

DONAL MCGOEY PHARMACY LIMITED

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2025

6. TANGIBLE FIXED ASSETS

	Motor vehicles €	Fixtures, fittings and equipment €	Total €
Cost or valuation			
At 1 November 2024	133,609	640,879	774,488
Additions	-	11,601	11,601
At 31 October 2025	<u>133,609</u>	<u>652,480</u>	<u>786,089</u>
Depreciation			
At 1 November 2024	18,333	538,790	557,123
Charge for the year on owned assets	26,722	32,749	59,471
At 31 October 2025	<u>45,055</u>	<u>571,539</u>	<u>616,594</u>
Net book value			
At 31 October 2025	<u>88,554</u>	<u>80,941</u>	<u>169,495</u>
At 31 October 2024	<u>115,276</u>	<u>102,089</u>	<u>217,365</u>

7. STOCKS

	2025 €	2024 €
Finished goods and goods for resale	<u>685,841</u>	<u>693,346</u>

The replacement cost of stocks did not differ significantly from cost.

DONAL MCGOEY PHARMACY LIMITED

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2025

8. DEBTORS

	2025 €	2024 €
Trade debtors	327,591	312,501
Amounts owed by group undertakings	4,063,328	4,062,236
Other debtors	228,276	211,531
Prepayments	64,037	70,526
Deferred taxation	2,324	-
Accrued income	-	5,722
	<u>4,685,556</u>	<u>4,662,516</u>

9. CREDITORS: Amounts falling due within one year

	2025 €	2024 €
Trade creditors	736,269	753,766
Corporation tax	1,786	3,335
Taxation and social insurance	50,288	47,805
Accruals	16,390	16,390
	<u>804,733</u>	<u>821,296</u>

10. DEFERRED TAXATION

	2025 €
At beginning of year	(697)
Charged to profit or loss	3,021
At end of year	<u>2,324</u>

The deferred taxation balance is made up as follows:

	2025 €	2024 €
Accelerated capital allowances	2,324	(697)
	<u>2,324</u>	<u>(697)</u>

DONAL MCGOEY PHARMACY LIMITED

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 OCTOBER 2025

11. PENSION COMMITMENTS

The company operates a defined contribution pension scheme and the assets of the scheme are held separately from those of the company in an independently administered fund. The pension cost charge represents contributions payable by the company to the fund, and amounted to €79,200 (2024 - €83,070).

12. RELATED PARTY TRANSACTIONS

Donal McGoey Pharmacy Limited is a subsidiary of Jonathan McGoey Pharmacy Limited, a company incorporated and registered in Ireland. Jonathan McGoey Pharmacy Limited owes Donal McGoey Pharmacy Limited €4,063,328 (2024 - €4,062,236) at the year end.

Other related party transactions

Mr. Donal McGoey is a related party in accordance with FRS102 Section 33 "Related Party Disclosures". The company operates from a premises at 66 Market Street, Ardee, Co. Louth which is owned by Donal McGoey. The rent payable during the financial year was €40,000 (2024 - €40,000) in respect of these premises.

13. PROVISION AVAILABLE FOR SMALL ENTITIES

In common with many other businesses of our size and nature, we use our auditors to prepare and submit tax returns to the revenue and assist with the preparation of the financial statements.

14. APPROPRIATION OF PROFIT & LOSS ACCOUNT

	2025 €	2024 €
Profit and loss account brought forward at the beginning of the year	5,393,542	5,367,448
Other movement in the profit and loss account	(27,598)	26,094
Profit and loss account carried forward at the end of the year	5,365,944	5,393,542

15. POST BALANCE SHEET EVENTS

There have been no significant events affecting the company since the year-end.

16. ULTIMATE PARENT UNDERTAKING

The ultimate parent undertaking is Jonathan McGoey Pharmacy Limited, a company incorporated and registered in Ireland.

17. APPROVAL OF FINANCIAL STATEMENTS

The board of directors approved these financial statements for issue on 8 December 2025